Stage IV cancer patients and psilocybin - Patient Interviews
Psilocybin is a novel agent that produces a profound alteration in your state of consciousness. To speak to a patient who went through this clinical trial, contact David Feuerherd at 310-215-0234. For more information on the trial, call Charles S. Grob, MD, at 310-222-3175.
The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) is one of the largest independent, not-for-profit biomedical research institutes in Los Angeles County. Affiliated with both the David Geffen School of Medicine at UCLA and the Harbor-UCLA Medical Center, the Institute has an annual budget of over $67 million and currently supports more than 1,000 research studies in areas such as cardiology, emerging infections, cancer, women\'s health, reproductive health, vaccine research, respiratory physiology, neonatology, molecular biology, and genetics.
LA BioMed also plays a pivotal role in the training of young physician ? scientists and scientists-to-be and is active in promoting the health and well being of nearby communities through community service programs that meet a variety of social and medical needs.
Contact: David Feuerherd
(LA BioMed)Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Feuerherd, David. "Stage IV cancer patients and psilocybin - Patient Interviews." Medical News Today. MediLexicon, Intl., 30 Sep. 2004. Web.
25 Jun. 2017. <http://www.medicalnewstoday.com/releases/14202.php>
Feuerherd, D. (2004, September 30). "Stage IV cancer patients and psilocybin - Patient Interviews." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.